Today: 9 June 2026
Experian PLC stock: $1bn buyback lifts share price — what to watch before Monday’s open
1 February 2026
1 min read

Experian PLC stock: $1bn buyback lifts share price — what to watch before Monday’s open

London, February 1, 2026, 08:31 GMT — Market closed.

  • Shares closed Friday up 2.3% at 2,758 pence after a new $1 billion buyback plan.
  • The programme runs to June 30, 2027 and starts with a first tranche arranged via JPMorgan.
  • Next near-term date on the calendar: Feb. 6 interim dividend payment.

Experian (EXPN.L) shares ended Friday up 2.3% at 2,758 pence after the credit data group launched a $1 billion share buyback, leaving investors to chew over the move ahead of Monday’s session.

The programme runs until no later than June 30, 2027, and allows repurchases of up to 89,789,942 shares. Experian said it is using the buyback to cut the share count and cover about $200 million of obligations under employee share plans, starting with a first tranche set up with JPMorgan Chase & Co..

The announcement landed with a stock that has been under pressure this year. Aarin Chiekrie at Hargreaves Lansdown called the buyback “clearly in response” to a roughly 20% year-to-date drop and said underlying trends “remain strong”. London South East

Even after Friday’s move, Experian is still about a third below its 52-week high, according to market data. Trading volume ran well above the recent daily average.

The size of the plan matters. Investors’ Chronicle said the buyback looked like a step up from smaller repurchases that tended to offset dilution from staff share schemes.

For the wider tape, credit bureaux still trade on lending volumes as much as earnings multiples. In a Jan. 21 update, Experian pointed to gains from a recovery in United States lending and steady demand for fraud-prevention services — a backdrop investors also read across to peers Equifax and TransUnion.

Chief executive Brian Cassin said on Jan. 21 that “with continued strong momentum, our full year expectations are unchanged.” The same statement said Experian will release full-year results for the year ending March 31, 2026 on May 20. Experian

With the market closed, the near-term read for investors is simple: how quickly the buyback starts to show up in the share count, and whether the stock can hold Friday’s pop when liquidity comes back on Monday.

But buybacks don’t fix the underlying debate. If lending demand softens again or competition worries flare up, the shares can slide regardless — and the company can always slow repurchases if it decides cash is better kept on the balance sheet.

The next hard date is Feb. 6, when the first interim dividend is due to be paid, according to the company’s financial calendar.

Stock Market Today

  • Pfizer Shares Drop Premarket Despite New FDA Approval for Hemophilia Drug
    June 9, 2026, 9:26 AM EDT. Pfizer shares declined 1.7% premarket to $25.62 following FDA approval of an expanded label for its hemophilia treatment Hympavzi, now authorized for patients aged 6 and older, including those with inhibitors-antibodies reducing clotting-factor therapy effectiveness. The drug offers a weekly subcutaneous injection alternative to frequent intravenous infusions. Despite the regulatory win, investor focus remains on Pfizer's obesity drug berobenatide, a monthly GLP-1 receptor agonist, competing with Novo Nordisk and Eli Lilly in weight loss treatments. Pfizer reported Q1 revenue of $14.5 billion, up 2% operationally, maintaining 2026 guidance of $59.5-$62.5 billion revenue and $2.80-$3.00 adjusted earnings per share, though earnings fell to 75 cents. Market reaction reflects caution over the company's longer path to profit growth amid patent expirations and competition.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop
Previous Story

Longsys Electronics stock set for Monday test after profit jump forecast and a sharp Friday drop

SSE share price flat at 2,422p as a key trading update looms this week
Next Story

SSE share price flat at 2,422p as a key trading update looms this week

Go toTop